Affluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix

Reuters02-02 14:30

Affluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix

Affluent Medical SA has completed the acquisitions of Caranx Medical and Artedrone, consolidating the three companies under a new name, Carvolix. The transaction was finalized with payments of €16.6 million and €11.4 million for Caranx Medical and Artedrone, respectively, paid entirely in Carvolix shares. As part of the strategic move, a €10 million first tranche of financing has been secured from Truffle Capital and Edwards Lifesciences at a subscription price of €2.34 per share, representing an 18.8% premium versus the last closing share price. The combined entity will focus on developing AI-driven mini-robots and biomimetic implants for interventional cardiology and stroke treatment, aiming to accelerate innovation and expand its addressable market. The first product launch, TAVIPILOT software, has already received FDA clearance and will be introduced in the US in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Affluent Medical SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: fr_reg_2269244_en), on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608361830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608361830","market":"nz","top_or_hot":-1,"title":"Affluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Affluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Affluent Medical SA has completed the acquisitions of Caranx Medical and Artedrone, consolidating the three companies under a new name, Carvolix. The transaction was finalized with payments of €16.6 million and €11.4 million for Caranx Medical and Artedrone, respectively, paid entirely in Carvolix shares. As part of the strategic move, a €10 million first tranche of financing has been secured from Truffle Capital and Edwards Lifesciences at a subscription price of €2.34 per share, representing an 18.8% premium versus the last closing share price. The combined entity will focus on developing AI-driven mini-robots and biomimetic implants for interventional cardiology and stroke treatment, aiming to accelerate innovation and expand its addressable market. The first product launch, TAVIPILOT software, has already received FDA clearance and will be introduced in the US in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Affluent Medical SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: fr_reg_2269244_en), on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Affluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAffluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-02 14:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Affluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Affluent Medical SA has completed the acquisitions of Caranx Medical and Artedrone, consolidating the three companies under a new name, Carvolix. The transaction was finalized with payments of €16.6 million and €11.4 million for Caranx Medical and Artedrone, respectively, paid entirely in Carvolix shares. As part of the strategic move, a €10 million first tranche of financing has been secured from Truffle Capital and Edwards Lifesciences at a subscription price of €2.34 per share, representing an 18.8% premium versus the last closing share price. The combined entity will focus on developing AI-driven mini-robots and biomimetic implants for interventional cardiology and stroke treatment, aiming to accelerate innovation and expand its addressable market. The first product launch, TAVIPILOT software, has already received FDA clearance and will be introduced in the US in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Affluent Medical SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: fr_reg_2269244_en), on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG0V08.USD","symbol_name":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3TDM9D:1","article_id":"2608361830","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608361830","pubTimestamp":1770013857,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Affluent Medical SA has completed the acquisitions of Caranx Medical and Artedrone, consolidating the three companies under a new name, Carvolix. The transaction was finalized with payments of 16.6 million and 11.4 million for Caranx Medical and Artedrone, respectively, paid entirely in Carvolix shares. As part of the strategic move, a 10 million first tranche of financing has been secured from Truffle Capital and Edwards Lifesciences at a subscription price of 2.34 per share, representing an 18.8% premium versus the last closing share price. The combined entity will focus on developing AI-driven mini-robots and biomimetic implants for interventional cardiology and stroke treatment, aiming to accelerate innovation and expand its addressable market. The first product launch, TAVIPILOT software, has already received FDA clearance and will be introduced in the US in early 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4082":"医疗保健设备","BK4588":"碎股","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4504":"桥水持仓","EW":"爱德华兹","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4585":"ETF&股票定投概念","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4567":"ESG概念","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD"},"translate_title":"Affluent Medical完成对Caranx Medical和Artedrone的收购，组建Carvolix","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":0.9},"content_text":"Affluent Medical Completes Acquisitions of Caranx Medical and Artedrone to Form Carvolix\n    \n\n        Affluent Medical SA has completed the acquisitions of Caranx Medical and Artedrone, consolidating the three companies under a new name, Carvolix. The transaction was finalized with payments of €16.6 million and €11.4 million for Caranx Medical and Artedrone, respectively, paid entirely in Carvolix shares. As part of the strategic move, a €10 million first tranche of financing has been secured from Truffle Capital and Edwards Lifesciences at a subscription price of €2.34 per share, representing an 18.8% premium versus the last closing share price. The combined entity will focus on developing AI-driven mini-robots and biomimetic implants for interventional cardiology and stroke treatment, aiming to accelerate innovation and expand its addressable market. The first product launch, TAVIPILOT software, has already received FDA clearance and will be introduced in the US in early 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Affluent Medical SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: fr_reg_2269244_en), on February 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608361830","isCrawlerRequest":true}